Physician profile
Robert A Winston
NPI 1992805444
$2,800.44
in general payments reported to CMS, 2019-2025
18 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $130 · 2021: $87.12 · 2022: $411 · 2023: $471 · 2024: $465 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.66 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $309.79 | 2019-2025 | Spravato, Invega, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $236.29 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.30 | 2022-2024 | Caplyta |
| Allergan, INC. | $158.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $151.63 | 2019-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $116.60 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $106.79 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $85.04 | 2019 | |
| Alkermes, INC. | $83.31 | 2019-2020 | |
| Lundbeck LLC | $72.07 | 2024 | Rexulti |
| Bausch Health US, LLC | $65.05 | 2019-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $49.01 | 2019-2020 | |
| Noven Therapeutics, LLC | $42.95 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $22.26 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $18.80 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.51 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.